Story perspectives

Indian Firms Launch Affordable Ozempic, Wegovy Generics After Patent Expiry

3/23/2026

Summary

Story summary

At least six Indian generic drugmakers launched affordable versions of Novo Nordisk's Ozempic and Wegovy after India's semaglutide patent expiration, cutting treatment costs by about 70%.
Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Zydus Lifesciences Ltd. introduced various formulations priced from 750 to 4,200 rupees per month (about $8 to $44).
Analysts predict more than 40 Indian firms will release over 50 variants, targeting domestic and international markets.

1 of 1

Story summary

At least six Indian generic drugmakers launched affordable versions of Novo Nordisk's Ozempic and Wegovy after India's semaglutide patent expiration, cutting treatment costs by about 70%.
Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Zydus Lifesciences Ltd. introduced various formulations priced from 750 to 4,200 rupees per month (about $8 to $44).
Analysts predict more than 40 Indian firms will release over 50 variants, targeting domestic and international markets.